1-10 of 10
Guy Gammon, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation

Brenda M. Sandmaier, MD, Samer K Khaled, MD, Betul Oran, MD, Guy Gammon, MD, Denise Trone, Olga Frankfurt, MD
Journal: Blood
Blood (2014) 124 (21): 428.
https://doi.org/10.1182/blood.V124.21.428.428
Published: 2014
Journal Articles

Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Jessica K Altman, MD, James M. Foran, MD, Keith W. Pratz, MD, Denise Trone, Guy Gammon, MD, Jorge E. Cortes, MD, Martin S Tallman, MD
Journal: Blood
Blood (2013) 122 (21): 623.
https://doi.org/10.1182/blood.V122.21.623.623
Published: 2013
Journal Articles

A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study

Todd Michael Cooper, Jemily Malvar, M.S., Jeannette Cassar, Elena Eckroth, CCRC, Richard Sposto, PhD, Paul Gaynon, MD, Steven Dubois, MD, Lia Gore, MD, Margaret E. Macy, M.D., Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Javier Oesterheld, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD
Journal: Blood
Blood (2013) 122 (21): 624.
https://doi.org/10.1182/blood.V122.21.624.624
Published: 2013
Journal Articles

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Martin S Tallman, MD, Gary Schiller, MD, Denise Trone, Guy Gammon, MD, Stuart Goldberg, MD, Alexander E Perl, MD, Jean-Pierre Marie, MD, Giovanni Martinelli, Mark Levis, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 494.
https://doi.org/10.1182/blood.V122.21.494.494
Published: 2013
Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Alexander E Perl, MD, Hervé Dombret, MD, Sabine Kayser, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 48.
https://doi.org/10.1182/blood.V120.21.48.48
Published: 2012
Journal Articles

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, James M. Foran, MD, FRCPC, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, M.D., Guy Gammon, MD, Denise Trone, Robert C Armstrong, Ph.D., Joyce James, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1507.
https://doi.org/10.1182/blood.V120.21.1507.1507
Published: 2012
Journal Articles

A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Todd Cooper, DO, Richard Sposto, PhD, Jeannette Cassar, Elena Eckroth, CCRC, Jemily Malvar, M.S., Paul Gaynon, MD, Steven Dubois, MD, Bill H Chang, MD, PhD, Lia Gore, MD, Keith J. August, M.D., M.Sc., Blythe Thomson, MD, Guy Gammon, MD, Daniel Magoon, Colleen E. Annesley, MD, Patrick Brown, MD
Journal: Blood
Blood (2012) 120 (21): 3605.
https://doi.org/10.1182/blood.V120.21.3605.3605
Published: 2012
Journal Articles

Absorption, Metabolism, and Excretion of Quizartinib (AC220), a FLT3 Tyrosine Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, in Healthy Male Volunteers

Jianke Li, Gayle Bresnahan, Guy Gammon, MD, Madhu Sanga, PhD, Christine Hale, MD, Tadashi Hashimoto, MSc, Stanley Gill, PhD, Joyce James
Journal: Blood
Blood (2012) 120 (21): 4327.
https://doi.org/10.1182/blood.V120.21.4327.4327
Published: 2012
Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Mark J. Levis, MD, PhD, Alexander E Perl, MD, Hervé Dombret, MD, Hartmut Döhner, MD, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Jorge E Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 673.
https://doi.org/10.1182/blood.V120.21.673.673
Published: 2012
Journal Articles

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

Jorge E. Cortes, Alexander E Perl, MD, Catherine C. Smith, MD, Tibor Kovacsovics, MD, Herve Dombret, Hartmut Dohner, MD, Bjorn Steffen, MD, Arnaud Pigneux, MD, PhD, Philippe Rousselot, MD, PhD, Juergen Krauter, MD, Giovanni Martinelli, MD, Elihu H. Estey, MD, Alan K Burnett, MD, Anthony D. Ho, Norbert Ifrah, Theo de Witt, MD, Robert Corringham, MD, Joyce James, PhD, David Lilienfeld, MD, Eugen Leo, MD, PhD, MBA, Guy Gammon, MD, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2576.
https://doi.org/10.1182/blood.V118.21.2576.2576
Published: 2011